NATCO Pharma (NATCOPHARM.BO) Earnings Analysis
NATCO Pharma (NATCOPHARM.BO) next reports earnings on 2026-08-18, consensus EPS 8.04 INR. Last quarter (2026-05-29) it missed with EPS 9.8 INR vs 15.76 INR est (-37.8%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E 11.61.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does NATCOPHARM.BO next report earnings?
| Next earnings date | 2026-08-18 |
|---|---|
| Consensus EPS estimate | 8.04 INR |
| Revenue estimate | 7.68B |
NATCOPHARM.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-29 | 9.8 INR | 15.76 INR | -37.8% | Miss |
| 2026-02-12 | 8.43 INR | 5.27 INR | +60% | Beat |
| 2025-11-14 | 29 INR | 24.56 INR | +18.1% | Beat |
| 2025-05-28 | 23 INR | 10.8 INR | +113% | Beat |
| 2025-02-12 | 7.4 INR | 19.4 INR | -61.9% | Miss |
| 2024-08-12 | 37.3 INR | 24.7 INR | +51% | Beat |
Beat rate: 4/6 (67%) over reported quarters with consensus data.
NATCOPHARM.BO valuation and analyst view
| Trailing P/E | 11.61 |
|---|---|
| Trailing EPS | 79.211 INR |
| Price / book | 1.79 |
| Dividend yield | 0.54% |
| Market cap | 167.42B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is NATCO Pharma (NATCOPHARM.BO)'s next earnings date?
NATCO Pharma is next scheduled to report on 2026-08-18, with a consensus EPS estimate of 8.04 INR and revenue estimate of 7.68B.
Did NATCOPHARM.BO beat earnings last quarter?
In its 2026-05-29 report, NATCOPHARM.BO posted EPS of 9.8 INR versus a 15.76 INR estimate — a miss of 37.8%.
What is NATCOPHARM.BO's earnings track record?
Over the last 6 reported quarters with consensus data, NATCOPHARM.BO beat estimates 4 times (67%).
What is NATCOPHARM.BO's current P/E ratio and EPS?
NATCOPHARM.BO trades at a trailing P/E of 11.61 on trailing EPS of 79.21149687448242 INR.
What do analysts rate NATCOPHARM.BO?
NATCOPHARM.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.